Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Articles

Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study. 

Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Educational interventions for patients, including both in-person and online methods, significantly reduced atopic dermatitis (AD) severity.

Study: Educational Interventions Substantially Reduce AD Severity

The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax. 

Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure

Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.

Research Shows Prior Authorization Denials Delay Critical Immunology Care

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Kevin J. Lynch, PharmD, BCPS, MBA

Articles